Autoantibody biomarkers identified and validated using Sengenics protein arrays have shown utility in a range of high-value applications—from early disease detection and patient stratification to treatment monitoring and prediction of treatment outcomes and immune-related adverse events (irAE).
Learn more about key applications for Sengenics technology and services.